The C2238/αANP variant is a negative modulator of both viability and function of coronary artery smooth muscle cells

PLoS One. 2014 Nov 17;9(11):e113108. doi: 10.1371/journal.pone.0113108. eCollection 2014.

Abstract

Background: Abnormalities of vascular smooth muscle cells (VSMCs) contribute to development of vascular disease. Atrial natriuretic peptide (ANP) exerts important effects on VSMCs. A common ANP molecular variant (T2238C/αANP) has recently emerged as a novel vascular risk factor.

Objectives: We aimed at identifying effects of CC2238/αANP on viability, migration and motility in coronary artery SMCs, and the underlying signaling pathways.

Methods and results: Cells were exposed to either TT2238/αANP or CC2238/αANP. At the end of treatment, cell viability, migration and motility were evaluated, along with changes in oxidative stress pathway (ROS levels, NADPH and eNOS expression), on Akt phosphorylation and miR21 expression levels. CC2238/αANP reduced cell vitality, increased apoptosis and necrosis, increased oxidative stress levels, suppressed miR21 expression along with consistent changes of its molecular targets (PDCD4, PTEN, Bcl2) and of phosphorylated Akt levels. As a result of increased oxidative stress, CC2238/αANP markedly stimulated cell migration and increased cell contraction. NPR-C gene silencing with specific siRNAs restored cell viability, miR21 expression, and reduced oxidative stress induced by CC2238/αANP. The cAMP/PKA/CREB pathway, driven by NPR-C activation, significantly contributed to both miR21 and phosphoAkt reduction upon CC2238/αANP. miR21 overexpression by mimic-hsa-miR21 rescued the cellular damage dependent on CC2238/αANP.

Conclusions: CC2238/αANP negatively modulates viability through NPR-C/cAMP/PKA/CREB/miR21 signaling pathway, and it augments oxidative stress leading to increased migratory and vasoconstrictor effects in coronary artery SMCs. These novel findings further support a damaging role of this common αANP variant on vessel wall and its potential contribution to acute coronary events.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects*
  • Atrial Natriuretic Factor / genetics
  • Atrial Natriuretic Factor / pharmacology*
  • Blotting, Western
  • C-Reactive Protein / genetics
  • C-Reactive Protein / metabolism
  • Cell Movement / drug effects*
  • Cell Survival / drug effects
  • Cells, Cultured
  • Coronary Vessels / drug effects
  • Coronary Vessels / metabolism
  • Coronary Vessels / pathology*
  • Cyclic AMP / pharmacology
  • Cyclic AMP Response Element-Binding Protein / genetics
  • Cyclic AMP Response Element-Binding Protein / metabolism
  • Cyclic AMP-Dependent Protein Kinases / genetics
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Humans
  • MicroRNAs / genetics
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / metabolism
  • Muscle, Smooth, Vascular / pathology*
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism
  • Oxidative Stress / drug effects
  • Phosphorylation / drug effects
  • Polymorphism, Genetic / genetics*
  • Proto-Oncogene Proteins c-akt / metabolism
  • RNA, Messenger / genetics
  • Reactive Oxygen Species / metabolism
  • Real-Time Polymerase Chain Reaction
  • Reverse Transcriptase Polymerase Chain Reaction
  • Signal Transduction / drug effects*

Substances

  • CREB1 protein, human
  • Cyclic AMP Response Element-Binding Protein
  • MIRN21 microRNA, human
  • MicroRNAs
  • Nerve Tissue Proteins
  • RNA, Messenger
  • Reactive Oxygen Species
  • neuronal pentraxin
  • Atrial Natriuretic Factor
  • C-Reactive Protein
  • Cyclic AMP
  • Proto-Oncogene Proteins c-akt
  • Cyclic AMP-Dependent Protein Kinases

Grants and funding

This work was supported by a grant (Ricerca Corrente) from the Italian Ministry of Health to MV and SR; by the 5‰ grant to MV and SR. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.